The SPAST antibody targets spastin, a protein encoded by the SPAST gene, which plays a critical role in microtubule dynamics. Spastin functions as an ATPase involved in severing microtubules, aiding in cytoskeletal remodeling essential for neuronal development, axonal transport, and synaptic plasticity. Mutations in SPAST are the most common cause of hereditary spastic paraplegia (HSP), a neurodegenerative disorder characterized by progressive lower-limb spasticity and weakness (primarily SPG4 subtype). Research using SPAST antibodies focuses on understanding spastin's molecular mechanisms, its interaction with microtubule networks, and how pathogenic mutations disrupt these processes. These antibodies are vital tools in Western blotting, immunofluorescence, and immunohistochemistry to detect spastin expression, localization, and dysfunction in cellular and animal models. Studies also explore spastin's role beyond HSP, including cancer (e.g., tumor invasiveness) and other neurological conditions. By elucidating spastin-related pathways, SPAST antibodies contribute to identifying therapeutic targets for HSP and related disorders, potentially bridging gaps in managing currently untreatable neurodegenerative diseases.